Remove Community Remove Complication Remove IT Remove Manufacturing
article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law Blog

FDA , Petitioners, a liquid nicotine manufacturer, sued FDA arguing that the Agency was arbitrary and capricious in rejecting the Petitioner’s Premarket Tobacco Application (“PMTA”) in violation of the Administrative Procedure Act (“APA”). FDA also directed manufacturers to produce detailed marketing plans.

article thumbnail

Urinary Incontinence Revisited: George Kuchel & Alison Huang

GeriPal

On our last podcast about urinary incontinence the song request was, “Let it go.” This time around several suggestions were raised. Eric suggested, “Even Flow,” by Pearl Jam. Someone else suggested, “Under Pressure,” but we’ve done it already. We settled on, “Oops…I did it again,” by Britney Spears. I suggested even flow. That’s a good one.

IT 120
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advance Care Planning Discussion: Susan Hickman, Sean Morrison, Rebecca Sudore, and Bob Arnold

GeriPal

Eric: We’ve got a lot talk to about out around advance care planning and serious illness communication. All decisions are made in advance, the question that we are debating is how far in advance and what to call it. Completion of advance directives and billing codes for advance care planning as quality metrics. Among other topics.

Illness 72
article thumbnail

Buckle Up: DOJ Initiates Rulemaking to Reschedule Marijuana

FDA Law Blog

DEA noted that “there is considerable variability in the cannabinoid concentrations and chemical constituency among marijuana samples and that the interpretation of clinical data related to marijuana is complicated.” and lacked accepted safety for use under medical supervision. 21 U.S.C. § 21 U.S.C. § NPRM at 44,619. NPRM at 44,601.

article thumbnail

Arsenicum album for Kerala school students: a bogus prophylaxis

Tiny Physician

However, there is no clinical trial on its effect on COVID 19 infection or its complications. Later, due to mass outrage from the scientific community, the label of ‘drug for treatment’ was changed to ‘immunity booster’ (5). Contrary to our beliefs, the second wave came and exposed all the weaknesses of our health system. Dipankar et.